CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges
Rudolf Werner, Alexander Haug, Christian Buske, Simon Heidegger, Anna L. Illert, Florian Bassermann, Peter Herhaus, Andreas Buck, Johannes Duell, Max S Topp, Sabrina Kraus, Hermann Einsele, Constantin Lapa, Markus Raderer, Georg Lenz, Stefan Habringer, Bastia… · Nuklearmedizin - NuclearMedicine · 2024 · Heft 02 · S. 57-61
Bibliografische Angaben
Zusammenfassung
AbstractC-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear medicine specialists, statements on the current clinical practice and future perspectives of this innovative concept were proposed and summarized in this opinion article. Experts concluded that i) CX…
